載入...
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
With 23 approvals in the US and other countries and four approvals outside US, antibodies are now widely recognized as therapeutic molecules. The therapeutic and commercial successes met by rituximab, trastuzumab, cetuximab and other mAbs have inspired antibody engineers to improve the efficacy of t...
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Landes Bioscience
2009
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2791310/ https://ncbi.nlm.nih.gov/pubmed/20073127 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|